SANIFIT
CSL is a global biotechnology company dedicated to improving health and well-being through innovative medicines, vaccines, and therapies. With a history of over a century, CSL's mission is to deliver biotherapeutics and vaccines that meet patient needs worldwide, focusing on areas such as rare and serious diseases, vaccines, and blood plasma products. The company emphasizes patient-centered care, research and development, sustainability, and community support, operating across various regions including the Americas, Asia Pacific, Middle East, and Europe. CSL's subsidiaries include CSL Behring, CSL Seqirus, and CSL Vifor, each specializing in different therapeutic areas. The company is committed to advancing science, improving public health, and fostering a values-based culture.
Industries
Nr. of Employees
small (1-50)
SANIFIT
45 Poplar Road, Parkville, Victoria, Australia
Patents
Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
US-12130296-B2
View DetailsIP and IP analogs dosage regimens for the treatment of ectopic calcifications
US-12070469-B2
View DetailsMethod for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
US-11162958-B2
View DetailsIP and IP analogs dosage regimens for the treatment of ectopic calcifications
US-10973838-B2
View Details
Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
US-12130296-B2
View DetailsIP and IP analogs dosage regimens for the treatment of ectopic calcifications
US-12070469-B2
View DetailsMethod for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
US-11162958-B2
View DetailsIP and IP analogs dosage regimens for the treatment of ectopic calcifications
US-10973838-B2
View DetailsProducts
Plasma-derived clotting factor concentrates and replacement therapies
Therapies derived from human plasma used to treat hereditary bleeding disorders and to replace missing clotting factors.
Immunoglobulin replacement therapies and hyperimmune preparations
Intravenous and subcutaneous immunoglobulin products for primary and secondary immunodeficiencies and hyperimmune preparations targeting specific pathogens.
Fibrinogen replacement therapies
Replacement therapy products for congenital fibrinogen deficiencies to support blood clot formation.
Seasonal and pandemic influenza vaccines
Seasonal influenza vaccines produced using cell-based and egg-based manufacturing, with formulations intended for older adults and scalable capacity for pandemic response.
Antivenoms and Q fever vaccine for public health programs
Specialized antivenoms for region-specific venomous species and vaccination products for Q fever produced to meet national public health needs.
Therapies for hereditary angioedema and related rare disorders
Therapeutic options for hereditary angioedema, including preventative and on-demand formulations, and treatments for conditions such as alpha-1 antitrypsin deficiency.
Plasma-derived clotting factor concentrates and replacement therapies
Therapies derived from human plasma used to treat hereditary bleeding disorders and to replace missing clotting factors.
Immunoglobulin replacement therapies and hyperimmune preparations
Intravenous and subcutaneous immunoglobulin products for primary and secondary immunodeficiencies and hyperimmune preparations targeting specific pathogens.
Fibrinogen replacement therapies
Replacement therapy products for congenital fibrinogen deficiencies to support blood clot formation.
Seasonal and pandemic influenza vaccines
Seasonal influenza vaccines produced using cell-based and egg-based manufacturing, with formulations intended for older adults and scalable capacity for pandemic response.
Antivenoms and Q fever vaccine for public health programs
Specialized antivenoms for region-specific venomous species and vaccination products for Q fever produced to meet national public health needs.
Therapies for hereditary angioedema and related rare disorders
Therapeutic options for hereditary angioedema, including preventative and on-demand formulations, and treatments for conditions such as alpha-1 antitrypsin deficiency.
Services
Programs to support patient access to therapies, including country-specific assistance and managed-access pathways.
Collaborative services with governments and public health bodies to supply vaccines and antivenoms and to plan seasonal and pandemic responses.
Operation of plasma collection centers and centralized testing laboratories to support biologics manufacturing supply chains.
Technical partnership services to improve antivenom production quality and quantity, including training in animal immunization and manufacturing processes and support for local facility development.
Development and provision of disease-specific educational content, patient stories and resources to support diagnosis, management and community engagement.
Programs to support patient access to therapies, including country-specific assistance and managed-access pathways.
Collaborative services with governments and public health bodies to supply vaccines and antivenoms and to plan seasonal and pandemic responses.
Operation of plasma collection centers and centralized testing laboratories to support biologics manufacturing supply chains.
Technical partnership services to improve antivenom production quality and quantity, including training in animal immunization and manufacturing processes and support for local facility development.
Development and provision of disease-specific educational content, patient stories and resources to support diagnosis, management and community engagement.
Expertise Areas
- Plasma protein therapeutics
- Vaccine research and manufacturing
- Cell and gene therapy development
- Rare disease therapeutic development (hematologic and immunologic)
Key Technologies
- Plasma fractionation and plasma-derived biologics manufacturing
- Recombinant protein expression and manufacture
- Cell-based vaccine production
- Egg-based vaccine production
News & Updates
CSL announced its half-year financial results for 2025, highlighting growth and strategic initiatives.
CSL has committed to a 40% reduction in Scope 1 and 2 emissions by 2030 as part of its sustainability strategy.
CSL continues to develop and launch new vaccines and therapies to address unmet medical needs.
CSL supports various community programs and patient advocacy organizations worldwide.
CSL's advancements in plasma therapies are improving treatment outcomes for patients with blood disorders.
CSL Seqirus's efforts in influenza vaccine technology are enhancing global pandemic preparedness.
CSL announced its half-year financial results for 2025, highlighting growth and strategic initiatives.
CSL has committed to a 40% reduction in Scope 1 and 2 emissions by 2030 as part of its sustainability strategy.
CSL continues to develop and launch new vaccines and therapies to address unmet medical needs.
CSL supports various community programs and patient advocacy organizations worldwide.
CSL's advancements in plasma therapies are improving treatment outcomes for patients with blood disorders.
CSL Seqirus's efforts in influenza vaccine technology are enhancing global pandemic preparedness.